Milademetan is an investigational new drug that is being evaluated to treat liposarcoma. It is a MDM2 inhibitor.

References



Milademetan Mdm2 TargetMol

Simulated mean plasma concentration‐time profiles of milademetan with

of PBPK modeling strategy. Treatment A single dose of milademetan

Milademetan Molecular Structure 3d, Flat Model, Mdm2 Inhibitor Ds3032

MDM2 Inhibitor Milademetan in Advanced Solid Tumors, or